{
  "symbol": "MO",
  "year": 2023,
  "period": "Q3",
  "curated_text": "Symbol: MO. Year: 2023. Period: Q3. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: FTC, U.S. Court of Appeals, District Court, the U.S. District Court, State, the U.S., Board of Directors, PM USA, UST Litigation, UST, fault and/or contributory. Context excerpt: competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and notice to the FTC in advance of certain corporate actions, including acquisitions, mergers or certain corporate restructurings.  In February 2022, the administrative law judge dismissed the FTC\u2019s complaint and, also in February 2022, FTC complaint counsel appealed the administrative law judge\u2019s decision to the FTC.  Oral argument with respect to the appeal occurred in September 2022.  After oral argument, the FTC asked for additional briefing, which was completed in December 2022.  In March 2023, ",
  "competition_summary": [
    {
      "competitor": "FTC",
      "mentions": 14,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "U.S. Court of Appeals",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "District Court",
      "mentions": 4,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 4,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "State",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "the U.S.",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "Board of Directors",
      "mentions": 2,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "PM USA",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "UST Litigation",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "UST",
      "mentions": 2,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    },
    {
      "competitor": "fault and/or contributory",
      "mentions": 1,
      "context": "competition in violation of Section 7 of the Clayton Antitrust Act (\u201cClayton Act\u201d).  If the FTC\u2019s challenge is successful, the FTC may order a broad range of remedies, including a requirement of FTC approval of future agreements related to the development, manufacture, distribution or sale of e-vapor products and prohibition against any officer or director of either Altria or JUUL serving on the other party\u2019s board of directors or attending meetings of the other party\u2019s board of directors and no"
    }
  ]
}